Terri Washington, MD
Endocrinology, Diabetes & Metabolism · Melrose Park, ILNPI 1114120722
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Novo Nordisk at 46.3% of the total. Reporting peaked in 2019 at $24,480 and has fallen 88.1% since, to $2,907 in 2025. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $207.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$22K
- Johnson & Johnson$21K
- Corcept Therapeutics$2K
- Amgen$526
- Insulet Corporation$517
- Dexcom, Inc.$249
- plus $2K from 23 others
What the payments were for
- Consulting fees$18,47839%
- Speaking & faculty fees$21,71045%
- Travel & lodging$2,2405%
- Food & beverage$5,16011%
- Education$2631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 88 | $22,171 |
| Johnson & Johnson | 38 | $20,976 |
| Corcept Therapeutics | 16 | $1,849 |
| Amgen(2 entities) | 6 | $526 |
| Insulet Corporation | 12 | $517 |
| Dexcom, Inc. | 9 | $249 |
| Tandem Diabetes Care, Inc. | 5 | $200 |
| Lilly USA, LLC | 8 | $182 |
| Sanofi-aventis U.S. LLC | 4 | $171 |
| Abbott | 8 | $162 |
| Boehringer Ingelheim | 4 | $161 |
| Recordati_rare_diseases_inc. | 4 | $101 |
| AstraZeneca | 5 | $95 |
| AbbVie | 5 | $95 |
| Astellas Pharma US Inc | 1 | $90 |
| IBSA Pharma Inc. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Sequel Med Tech, LLC | 1 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Theracosbio, LLC | 1 | $20 |
| Mannkind Corporation | 1 | $20 |
| Antares Pharma, Inc. | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $16 |
| BETA Bionics, Inc. | 2 | $16 |
| Bayer | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $11 |
| Senseonics, Incorporated | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,850 in reported general payments places this provider in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 280 | $401,982 |
| MounjaroTirzepatide | 129 | $176,551 |
| JardianceEmpagliflozin | 158 | $145,858 |
| RybelsusSemaglutide | 35 | $56,307 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 31 | $46,544 |
| FarxigaDapagliflozin Propanediol | 52 | $41,557 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $39,338 |
| TrulicityDulaglutide | 28 | $35,527 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 39 | $33,765 |
| TradjentaLinagliptin | 36 | $28,782 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $22,049 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $19,862 |
| JanuviaSitagliptin Phosphate | 22 | $19,657 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $19,365 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $19,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $22,171 | $464,174334 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $182 | $216,693180 claims |
| Boehringer IngelheimJardiance, Tradjenta | $161 | $174,640194 claims |
| AstraZenecaFarxiga | $95 | $41,55752 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $24 | $4,370250 claims |
| AbbVieSynthroid | $95 | $4,30757 claims |
| Sanofi-aventis U.S. LLCLantus | $171 | $3,20125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Melrose Park
- Maha AbboudMelrose Park$219K
- Rim JoubranMelrose Park$19K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.